Despite these differences, combining DDR inhibitors together with RT renders both HPV-positive and HPV-negative radioresistant cells more sensitive to RT, offering possibilities for new therapies for patients with recurrent HNSCC, a population with limited therapeutic options. The gene discussed is DDR1; the disease is head and neck squamous cell carcinoma.